ArticleClinical kidney journal2026
Endothelial biomarkers predict kidney and cardiovascular outcomes after acute kidney injury.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute kidney injury (AKI) is common in hospitalized patients, and post-injury biological processes activated after the initial insult may determine recovery or sustained damage. Identifying these processes may offer opportunities for early intervention, and biomarkers can serve as valuable tools in this context. We hypothesized that endothelial biomarkers-reflecting endothelial dysfunction or damage-predict adverse clinical outcomes following AKI. Methods: In a single-center cohort of 93 consecutive patients with in-hospital mild AKI, a panel of endothelial (sFlt-1, CD138, and sVCAM-1) and renal stress (IGFBP7, TIMP2, and their product [IGFBP7]*[TIMP2]) biomarkers was measured at diagnosis. Associations with in-hospital mortality, AKI duration ≥7 days, new-onset cardiovascular disease (CVD), and renal nonrecovery were examined using regression analyses. Results: Endothelial biomarkers were more closely associated with adverse outcomes than renal stress biomarkers in this cohort. After adjustment, each 100-unit increase in sFlt-1 was independently associated with higher odds of in-hospital death (OR 1.034 [1.007-1.062], Conclusions: Endothelial biomarkers, particularly sFlt-1 and CD138, provide insight into vascular health following AKI and independently predict clinical outcomes. Their integration into clinical models may improve risk stratification, supporting personalized post-AKI care strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.